Milestone reinforces leadership in AI-powered breast cancer detection
WELLINGTON,New Zealand,Oct. 25,2024 --Volpara Health,a Lunit company and global leader in artificial intelligence (AI)-powered breast health solutions,has reached a significant milestone: the publication of the 300th peer-reviewed scientific paper using Volpara results. This accomplishment underscores Volpara's commitment to advancing breast cancer detection and personalized care through evidence-based AI technologies.
The need for robust,peer-reviewed validation in mammography AI is essential to its clinical adoption. Areview of 100 CE-marked AI products in radiology revealed that 64% lacked peer-reviewed evidence of efficacy. Volpara,in contrast,leads the mammography AI industry with the most peer-reviewed scientific papers,demonstrating its innovative technologies are rigorously tested,and clinically validated.
"Reaching 300 studies reflects the deep trust our technology has earned within both the academic and clinical communities," said Teri Thomas,CEO of Volpara Health and CBO of Lunit. "Our commitment to peer validation provides important evidence of our AI solutions' ability to deliver measurable improvements in detection and patient outcomes."
Two recent studies showcase the benefits of Volpara's AI technology.
Breast density-based mammogram ordering enhances interpretation
Enhancing Radiologist Reading Performance by Ordering Screening Mammograms Based on Characteristics That Promote Visual Adaptation,shows how ordering mammograms based on breast density can improve radiologists' performance. By arranging mammograms from low to high volumetric breast density (VBD),radiologists reduced reading time and increased specificity from 86% to 89%,leading to greater accuracy in detecting cancer. Commenting in an editorial on the study,Dr. Lars Grimm explained,"Deliberate ordering of screening mammograms could be introduced into workflows very easily because it dovetails with existing batch-reading strategies."
Study confirms Volpara's AI identifies Women at higher risk for missed cancers
Breast Density Effect on the Sensitivity of Digital Screening Mammography in a UK Cohort,used Volpara's AI-powered algorithms to determine how breast density affects cancer detection in the UK. The study confirmed that Volpara's technology effectively identifies women at higher risk for missed cancers on mammography,reinforcing the importance of personalized screening strategies.
Melissa Hill,PhD,Senior Imaging Scientist and Global Research Lead at Volpara Health,emphasized the significance of scientific rigor: "Our research collaborations and commitment to innovation have brought us to this important milestone. Each published paper puts our technology to the test,and robust results strengthen the trust clinicians place in Volpara to help improve patient care."
The company's journey from its first to its 300th peer-reviewed paper reflects over 15 years of innovation and investment in research. Volpara remains committed to pushing the boundaries of AI to improve breast health.
For more information about Volpara Health and new research to be presented at RSNA 2024,visit volparahealth.com/rsna2024.
About Volpara Health
Volpara Health is on a mission to save families from cancer with AI-powered software that helps healthcare providers better understand cancer risk,guide personalized care decisions,and recommend additional imaging and interventions. Used in over 3,500 facilities by more than 5,600 technologists worldwide. Volpara's software impacts nearly 18M patients,supports over 3.6M annual cancer risk assessments,and integrates seamlessly with electronic health records and imaging systems. Volpara helps radiologists quantify dense breast tissue with precision and technologists produce mammograms with optimal positioning,compression,and dose. Volpara software also streamlines operations to ease compliance and accreditation. Volpara,a Lunit company,is headquartered in Wellington,and has an office in Seattle. Volpara is the trusted partner of leading healthcare institutions globally. For more information,visitwww.volparahealth.com.
Logo - /up/2024/1025/24102520134495482491.jpg